Please assess the completion status of the following clinical trial:

Trial Title: Cell Therapy in Chronic Ischemic Heart Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of chronic, severe, diffuse, multivessel atherosclerotic coronary artery disease (CAD) referred for CABG.~* Echocardiogram-assessed LVEF between 25 and 55% (Simpson's rule).~* Angina (or equivalent) functional class II to IV (Canadian Cardiovascular Society) despite maximally tolerated medical therapy.~* Abnormal myocardial perfusion tests:~  i. Cardiac scintigraphy ii. Magnetic resonance imaging iii. Dobutamine-atropine stress-echocardiogram~* Non-candidates for a percutaneous coronary intervention (PCI) due to ANY of the following:~  i. High risk lesion ii. Extensive lesion iii. Diffuse, small vessel disease~* Non-candidates for a complete CABG, or candidates for a complete CABG in whom, according to an expert panel, there is a high probability of failure of the grafts due to the extension and severity of the disease, with diffuse, small vessel involvement.~* To provide a signed, written informed consent, according to the National Guidelines for Clinical Trials.~Exclusion Criteria:~* Severe valve heart disease requiring surgical repair.~* Serologic diagnostic of Chagas' disease.~* Symptoms of heart failure, even from an ischemic etiology, in the absence of objectively documented myocardial ischemia.~* Malignant ventricular arrhythmias (like VT), unless an ICD have been placed.~* Any acute coronary syndrome in the past 3 months.~* End-stage renal disease requiring maintenance dialysis.~* History of neoplasia.~* Drug or alcohol abuse.~* Life expectancy below 2 years.~* Enrollment in any cell therapy trial in the past 2 years.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).